A new publication reports that 91% of colorectal cancers were detected at 90% specificity in a completed prospective trial using Volition's Nu.Q(TM) assays
PR Newswire,
/PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) today announced the publication of a research paper entitled " Circulating…